Cisplatin remains the treatment cornerstone for bladder cancer, either in neoadjuvant or in metastatic (cisplatin-gemcitabine or dose-dense methotrexate, vinblastine, and doxorubicin). Although the toxicity profile of cisplatin has been known for a long time, rapid and adequate management of adverse effects is important in order to avoid dose reductions, treatment delays, or cessation.